The animal world is full of species that can perform astonishing, and sometimes disgusting, feats. Take vultures, for example. “They eat this rotten meat that is full of pathogens and toxins, and they stay healthy,” Neta Raab told BioWorld. Raab is the co-founder and CEO of Wild Biotech Ltd., an Israeli startup that is seeking to understand gut microbiome contributions to these animal superpowers, and harness them for therapeutic use.

Zenas Biopharma LLC launched on March 23 as a U.S. funded cross-border biotech company targeting autoimmune diseases in China. The company, headquartered in Miromar Lakes, Fla., is founded and funded by Tellus Bioventures LLC and Fairmount Funds Management LLC.

Eliem Therapeutics Inc. is old-fashioned in the useful ways. The company is going after extremely large indications, including chronic pain and major depression. “We’re really passionate about these large markets,” Eliem President and CEO Bob Azelby told BioWorld. “These patients live in the shadows… There’s so many people suffering.”

Researchers at the University of California at San Diego have used a gene therapy approach to treat pain by specifically suppressing the Nav 1.7 ion channel in the spinal cord, both preventing and reversing pain in several animal models with distinct underlying reasons for pain.

Medi-Scan Inc. has emerged from stealth mode with cloud-based software that converts the data on ultrasound analog 2D grayscale images into a digital 3D high-definition (HD) format in less than two minutes. The company is currently focusing its efforts on the heart and lungs, with the aim of providing quick, point-of-service evaluation and triaging of patients with heart disease and other conditions, including COVID-19.

TORONTO – Novel. Unique. Revolutionary. Terms too often used to indiscriminately describe medical devices that have yet to prove their stuff. Not so at France’s Ministry of Health which takes care to deem winning devices under its Forfait Innovation (FI) program “truly innovative, not simply incremental developments.” Last week the FI awarded Vancouver, British Columbia’s Evasc Neurovascular Inc. €2.76 million (US$3.37 million) to test its CE-marked Eclips for treating intracranial bifurcation aneurysms during a 119-patient trial at 20 French sites in 2021.

Bionaut Labs emerged from five years in stealth mode raising $20 million to develop Bionauts, microrobots designed to deliver therapies to treat brain disorders. The financing will support the company’s therapeutic program in glioma through preclinical development and further research and development in Huntington’s disease.

Bionaut Labs emerged from five years in stealth mode raising $20 million to develop Bionauts, microrobots designed to deliver therapies to treat brain disorders. The financing will support the company’s therapeutic program in glioma through preclinical development and further research and development in Huntington’s disease. Khosla Ventures led the financing with participation by Upfront Ventures, Revolution LLC, BOLD Capital Partners, and Compound.

If Marvel’s Peter Parker had chosen to apply his graduate work in biochemistry and his web-shooters to medicine, he might have created something like Nanomedic Technologies Ltd.’s Spincare system. The system uses a hand-held medical gun that prints a flexible, transparent layer of artificial skin directly on a wound or burn. The Electrospun Healing Fiber (EHF) technology creates a waterproof, protective nano polymer matrix.

RNA has “huge potential” as a therapeutic modality and is beginning to deliver on that potential. But “manufacturing RNA has issues in production, delivery and performance,” Thomas Barnes told BioWorld. Barnes is the CEO of startup Orna Therapeutics LLC, which has the goal of addressing those issues with oRNA, an engineered form of circular RNA.